Sino-Argi Leading Biosciences (SHG:603970) — Stock Price

CN¥10.64 CNY
▲ 1.72% today

Sino-Argi Leading Biosciences (SHG:603970) is currently trading at CN¥10.64 CNY, up 1.72% today. Over the past 52 weeks, shares have ranged between CN¥9.63 and CN¥14.45. This page tracks Sino-Argi Leading Biosciences's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 603970 market cap overview.

Sino-Argi Leading Biosciences (603970) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Sino-Argi Leading Biosciences's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.

Sino-Argi Leading Biosciences Income Statement — Revenue, Profit & Earnings by Year

Sino-Argi Leading Biosciences's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue CN¥11.24 Billion CN¥10.60 Billion CN¥10.46 Billion CN¥11.70 Billion CN¥8.82 Billion
Cost of Revenue CN¥10.50 Billion CN¥9.88 Billion CN¥9.76 Billion CN¥10.97 Billion CN¥8.29 Billion
Gross Profit CN¥739.80 Million CN¥718.27 Million CN¥701.54 Million CN¥726.80 Million CN¥530.36 Million
Research & Development CN¥66.41 Million CN¥66.74 Million CN¥65.36 Million CN¥45.79 Million CN¥37.53 Million
SG&A CN¥163.20 Million CN¥79.35 Million CN¥74.75 Million CN¥70.28 Million CN¥65.37 Million
Total Operating Expenses CN¥10.89 Billion CN¥416.80 Million CN¥386.14 Million CN¥401.91 Million CN¥291.24 Million
Operating Income CN¥347.94 Million CN¥301.47 Million CN¥315.41 Million CN¥324.89 Million CN¥239.13 Million
EBITDA — CN¥345.14 Million CN¥341.62 Million CN¥365.13 Million CN¥289.91 Million
EBIT — CN¥335.07 Million CN¥330.76 Million CN¥352.45 Million CN¥279.76 Million
Interest Expense CN¥22.97 Million CN¥32.96 Million CN¥15.63 Million CN¥43.87 Million CN¥39.52 Million
Income Before Tax CN¥239.42 Million CN¥302.11 Million CN¥315.13 Million CN¥325.69 Million CN¥240.24 Million
Income Tax Expense — CN¥73.23 Million CN¥67.55 Million CN¥77.80 Million CN¥54.60 Million
Net Income CN¥172.53 Million CN¥203.38 Million CN¥224.84 Million CN¥210.32 Million CN¥170.31 Million

Sino-Argi Leading Biosciences Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Sino-Argi Leading Biosciences's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets CN¥4.91 Billion CN¥5.60 Billion CN¥6.01 Billion CN¥6.24 Billion CN¥4.74 Billion
Total Current Assets CN¥4.65 Billion CN¥5.35 Billion CN¥5.74 Billion CN¥5.98 Billion CN¥4.50 Billion
Cash & Equivalents — — — — —
Short-term Investments CN¥864.33 Million CN¥1.00 Billion CN¥792.20 Million CN¥1.00 Billion CN¥506.93 Million
Net Receivables CN¥1.45 Billion CN¥1.74 Billion CN¥1.71 Billion CN¥437.29 Million CN¥237.23 Million
Inventory CN¥1.47 Billion CN¥1.57 Billion CN¥1.54 Billion CN¥1.56 Billion CN¥1.72 Billion
Property, Plant & Equipment — — — CN¥60.39 Million CN¥73.77 Million
Goodwill — CN¥0.00 CN¥0.00 — —
Total Liabilities CN¥3.18 Billion CN¥3.92 Billion CN¥4.41 Billion CN¥4.76 Billion CN¥3.46 Billion
Total Current Liabilities CN¥3.15 Billion CN¥3.90 Billion CN¥4.39 Billion CN¥4.63 Billion CN¥3.43 Billion
Long-term Debt — — — CN¥100.00 Million —
Net Debt CN¥308.29 Million CN¥227.49 Million CN¥-215.57 Million CN¥-1.02 Billion CN¥-9.79 Million
Total Stockholder Equity CN¥1.58 Billion CN¥1.52 Billion CN¥1.44 Billion CN¥1.32 Billion CN¥1.17 Billion
Retained Earnings CN¥906.25 Million CN¥858.15 Million CN¥791.09 Million CN¥691.60 Million CN¥548.47 Million

Sino-Argi Leading Biosciences Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Sino-Argi Leading Biosciences generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow CN¥-78.31 Million CN¥307.40 Million CN¥-919.85 Million CN¥1.54 Billion CN¥325.42 Million
Capital Expenditures CN¥1.37 Million CN¥2.18 Million CN¥4.37 Million CN¥3.44 Million CN¥3.99 Million
Free Cash Flow CN¥-79.68 Million CN¥305.21 Million CN¥-924.22 Million CN¥1.53 Billion CN¥321.43 Million
Investing Cash Flow — CN¥-199.52 Million CN¥225.56 Million CN¥-566.93 Million CN¥78.02 Million
Financing Cash Flow — CN¥-270.83 Million CN¥-328.26 Million CN¥-123.27 Million CN¥-313.20 Million
Dividends Paid CN¥143.11 Million CN¥145.02 Million CN¥123.44 Million CN¥67.20 Million CN¥57.60 Million
Stock-Based Compensation — — — — —
Depreciation CN¥20.75 Million CN¥21.20 Million CN¥22.05 Million CN¥23.40 Million CN¥19.39 Million
Change in Cash CN¥-181.16 Million CN¥-163.53 Million CN¥-1.04 Billion CN¥755.62 Million CN¥98.54 Million

Sino-Argi Leading Biosciences Earnings History — EPS Actual vs. Analyst Estimates

Track Sino-Argi Leading Biosciences's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 16, 2025 — — —
Mar 31, 2023 0.20 — —
Dec 31, 2022 0.15 — —
Sep 30, 2022 0.11 — —
Jun 30, 2022 0.35 — —
Mar 31, 2022 0.17 — —
Dec 31, 2021 0.12 — —
Sep 30, 2021 0.09 — —